Targeting a specific metabolic pathway to treat acute myeloid leukemia.
Official title: Targeting Hexosamine Biosynthetic Pathway and O-GlcNAcylation to Treat Acute Myeloid Leukemia
Funded at Louis Stokes Cleveland VA Medical Center · NIH-10925521 · Data updated 2026-11-12
This study is exploring a new way to treat acute myeloid leukemia (AML) by targeting a specific pathway that cancer cells use to survive, with the hope of making treatments more effective and safer, especially for older veterans who often struggle with current options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louis Stokes Cleveland VA Medical Center NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2025 |
| NIH project number | 1I01BX005941-01A1 |
| Project ID | NIH-10925521 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 65 and older, particularly veterans diagnosed with acute myeloid leukemia.
✕Less likely to help
Patients with other forms of leukemia or those who are not veterans may not receive direct benefits from this research.
What this research studies
This research investigates a new treatment approach for acute myeloid leukemia (AML), focusing on the hexosamine biosynthetic pathway and its role in cancer cell survival. The study aims to understand how AML cells utilize this pathway for energy and growth, leading to increased resistance to current therapies. By inhibiting this pathway, the research seeks to selectively kill AML cells while sparing normal cells, potentially reducing relapse rates. The research is particularly relevant for older veterans, who have a significantly lower survival rate with existing treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for acute myeloid leukemia, improving survival rates and quality of life for patients.
How similar studies have gone: While this approach is innovative, previous research has shown promise in targeting metabolic pathways in cancer treatment, suggesting potential for success.
Where this research is happening
-
Louis Stokes Cleveland VA Medical Center
Cleveland, United States Active
Researchers
- Principal investigator: Ramakrishnan, Parameswaran — Louis Stokes Cleveland VA Medical Center
- Study coordinator: Ramakrishnan, Parameswaran
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.